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Abstract To assess the prognostic value of aortic valve
and mitral valve/annulus calcifications for cardiovascular
events in heavily smoking men without a history of car-
diovascular disease. Heavily smoking men without a
cardiovascular disease history who underwent non-con-
trast-enhanced low-radiation-dose chest CT for lung can-
cer screening were included. Non-imaging predictors
(age, smoking status and pack-years) were collected and
imaging-predictors (calcium volume of the coronary ar-
teries, aorta, aortic valve and mitral valve/annulus) were
obtained. The outcome was the occurrence of cardiovas-
cular events. Multivariable Cox proportional-hazards re-
gression was used to calculate hazard-ratios (HRs) with
95 % confidence interval (CI). Subsequently, concor-
dance-statistics were calculated. In total 3111 individuals
were included, of whom 186 (6.0 %) developed a car-
diovascular event during a follow-up of 2.9 (Q1–Q3,
2.7–3.3) years. If aortic (n = 657) or mitral (n = 85)
annulus/valve calcifications were present, cardiovascular
event incidence increased to 9.0 % (n = 59) or 12.9 %
(n = 11), respectively. HRs of aortic and mitral valve/
annulus calcium volume for cardiovascular events were
1.46 (95 % CI, 1.09–1.84) and 2.74 (95 % CI, 0.92–4.56)
per 500 mm3. The c-statistic of a basic model including
age, pack-years, current smoking status, coronary and
aorta calcium volume was 0.68 (95 % CI, 0.63–0.72),
which did not change after adding heart valve calcium
volume. Aortic valve calcifications are predictors of fu-
ture cardiovascular events. However, there was no added
prognostic value beyond age, number of pack-years,
current smoking status, coronary and aorta calcium vol-
ume for short term cardiovascular events.
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Introduction
Cardiovascular disease is one of the most important causes
of death in heavy cigarette smokers [1]. Calcifications of
the coronary arteries, aorta and heart valves are known
predictors for cardiovascular events and can be quantified
with electrocardiography (ECG) synchronized computed
tomography (CT) [2–9].
Lung cancer screening studies such as the Dutch Belgian
randomized lung cancer screening trial (NELSON) and the
national lung screening trial (NLST) involve CT imaging
of the chest without ECG synchronization [1, 10, 11].
These screening studies are aimed at detecting lung cancer,
but they can also provide information about other diseases
such as chronic obstructive pulmonary disease and car-
diovascular disease [12, 13]. Despite the absence of ECG
triggering, recent studies have shown that coronary and
aortic calcifications can be quantified on lung cancer
screening chest CT images and can provide prognostic
information on future cardiovascular events [14–17]. Since
smoking is not only a risk factor for lung cancer, but also
for cardiovascular disease, these results could be beneficial
for the effectiveness of chest CT screening in substantial
smokers.
A previous study has shown that it is technically pos-
sible to detect and quantify cardiac valve calcifications on
low-dose unenhanced non-triggered lung cancer screening
CT images [18]. However, the prognostic value of heart
valve calcifications for cardiovascular disease in heavily
smoking men is unknown.
The aim of the current study was to assess the prognostic
value of calcifications of the aortic valve and mitral valve/
annulus for cardiovascular events in 3111 heavily smoking
men without a history of cardiovascular disease, par-
ticipating in the NELSON lung cancer screening trial.
Materials and methods
Study population
Heavily smoking or formerly smoking subjects without a
history of cardiovascular disease who underwent a chest
CT-scan as part of the NELSON screening trial (Clinical
Trial Registration ISRCTN63545820) at the University
Medical Centers of Groningen and Utrecht were included.
The NELSON trial was approved by the Dutch Minister
of Health and the local Ethical Reseach Boards of the
participating hospitals. The study population was recruited
between September 2003 and April 2006. Questionnaires
were sent to individuals living in four regions (Groningen,
Utrecht, Haarlem, and Leuven) [10, 11]. The addresses of
individuals aged between 50 and 75 were obtained from the
population registries. Based on the questionnaires, 15,822
individuals with high lung cancer risk were included. Only
individuals were included who had smoked 15 cigarettes or
more per day during 25 years, or 10 cigarettes or more per
day during 30 years, and were still smoking or had quit
\10 years ago [10]. The study population was divided into
a screening group of 7915 individuals who underwent four
chest CT scans and a control group of 7907 individuals.
Exclusion criteria included not enough cardiopulmonary
reserve to undergo surgery, current or past renal cancer,
melanoma or breast cancer, and diagnosis of lung cancer
within 5 years before filling in the questionnaire and lung
cancer that is still treated, and a chest CT scan within
1 year before filling out the questionnaire [11].
For the current study, subjects from the screening groups
of two centers (Groningen and Utrecht) were included for
efficiency reasons. Since only 89 women were present in
this sample, women were excluded. All subjects underwent
a baseline chest CT scan between January 2004 and De-
cember 2007.
Image acquisition
Non-contrast enhanced images of the chest were acquired
without ECG gating on 16-slice CT systems (Brilliance 16P
or Mx8000 IDT, Philips Healthcare, Best, The Netherlands
or Sensation 16, SiemensHealthcare, Forchheim, Germany).
Low radiation dose protocolswere usedwith a collimation of
16 9 0.75 mm, a tube voltage of 120 kV for participants
weighing less than 80 kg or 140 kV for participants weigh-
ing 80 kg or more. Tube current settings varied based on
hardware and participant weight.
Data collection
Information about non-imaging predictors (age, smoking
status and pack years) was collected from the baseline
NELSON questionnaires. Calcium volume of the aorta and
coronary arteries were previously obtained using an in-
house developed software package as described by Isgum
et al. [19, 20] and Mets et al. [15]. This software package
was also used in the current study for quantification of
aortic and mitral valve calcifications. Calcium volume of
the aortic valve and the mitral valve/annulus were quanti-
fied manually. Since it is very difficult to differentiate the
mitral annulus from the mitral valve on a non-contrast
enhanced low radiation dose non-gated chest CT, the val-
ues were taken together as total mitral valve calcification.
In the remainder, ‘mitral valve calcification’ refers to cal-
cification of both valve and annulus (if applicable). The
volume (mm3) of regions with a density of 130 Hounsfield
units or more was determined. If no calcifications were
present, the volume was set at 0 mm3. A previous study by
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van Hamersvelt et al. [18] has shown that the inter-observer
and inter-examination variability of cardiac valve mea-
surements is sufficient to allow for longitudinal studies,
especially for the aortic valve.
The outcome variable was the occurrence of cardio-
vascular events, which was obtained by linkage of subjects
with the National Death Registry and the National Registry
of Hospital Discharge Diagnoses. Both fatal and nonfatal
cardiovascular events that occurred between January 1995
and January 2008 were included. Cardiovascular events
were classified according to the World Health Organiza-
tion’s International Classification of Diseases [21]. Car-
diovascular events included hypertensive disease, ischemic
heart disease, heart failure, diseases of arteries, arterioles
and capillaries, cerebrovascular disease, or other heart
disease. Individuals with a history of cardiovascular dis-
ease, defined as a hospitalization for a cardiovascular event
in the 10 years before the CT, were excluded. If a subject
was admitted to a hospital for a cardiovascular disease and
died later on due to a cardiovascular disease, cardiovas-
cular death was chosen as the outcome value. If a subject
was admitted multiple times to a hospital for a cardiovas-
cular disease, the diagnosis at first discharge was used.
Data analysis
Missing data were imputed using single linear regression
imputation since less than 5 % of data were missing and
missing data were random. Baseline characteristics were
compared between individuals with a cardiovascular event
and individuals without a cardiovascular event using the
Mann–Whitney U test (continuous data) or the Chi square
test (frequency data). Calcification volumes of the aorta
and coronaries and the aortic and mitral valves were
truncated at the 99th percentile as previously described
[15]. Furthermore, the number of pack years was truncated
at 50 years since higher numbers of pack years did not
increase cardiovascular risk [15]. In order to perform a Cox
proportional hazards (PH) regression analysis, the PH as-
sumption was checked by the Schoenfield residuals. A
multivariable prediction model was made for cardiovas-
cular risk using Cox PH regression analysis. Based on this
prediction model the hazard ratios (HRs) of the predictors
were calculated with 95 % confidence intervals (CI).
Subsequently, a bootstrap analysis was performed to cor-
rect for over-optimism. An age-adjusted survival curve was
evaluated by presence and absence of aortic valve
calcifications.
Concordance-statistics (c-statistics) were calculated to
evaluate the discriminative capacity between a subject with
and a subject without a cardiovascular event [22, 23].
Data are presented as medians (first quartile–third
quartile) unless otherwise stated. Statistical analyses were
performed using R version 3.0.2 (R Foundation for Sta-
tistical Computing, Vienna, Austria) and SPSS Statistics
version 20 (SPSS Inc, Chicago, Illinois, The United States).
Statistical testing was two-sided, and a p value below 0.05
was considered statistically significant.
Results
In total 3111 men were included, 1620 from the region of
Groningen and 1491 from the region of Utrecht. Detailed
characteristics of the individuals are listed in Table 1. In
total 0.13 % of data for 6 variables was missing. Therefore,
Table 1 Demographic characteristics of the 3111 lung cancer screening participants
Variable No event (N = 2925) CV event (N = 186) P-value
Age (years) 59.2 (55.9–63.3) 60.8 (57.1–65.1) 0.000*
Length height (cm) 179.0 (174.8–183.0) 178.0 (175.0–183.0) 0.560*
Number of current smokers (%) 1658 (56.7 %) 128 (68.8 %) 0.000**
Pack years 38.0 (28.0–46.2) 38.7 (29.7–49.5) 0.019*
Coronary calcification volume (mm3) 126.4 (6.8–528.6) 590.2 (152.1–1441.4) 0.000*
Aortic calcification volume (mm3) 419.4 (74.0–1365.9) 1352.7 (301.7–3128.6) 0.000*
Number of individuals with aortic valve calcifications 598 (20.4 %) 59 (31.7 %) 0.000**
Aortic valve calcification volume (mm3) 96.3 (39.7–235.4) 179.1 (71.6–387.1) 0.002*
Number of individuals with mitral valve/annulus calcifications 74 (2.5 %) 11 (5.9 %) 0.006**
Mitral valve/annulus calcification volume (mm3) 140.8 (54.4–357.1) 216.9 (44.5–356.4) 0.977*
Values are medians (first quartile–third quartile) or numbers (percentages)
Significant values are marked bold
*P-value based on Mann–Whitney U test
**P-value based on Chi square test
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missing data were imputed using single linear regression
imputation. In total 186 individuals (6.0 %) developed a
cardiovascular event during a follow-up of 2.9 (Q1–Q3,
2.7–3.3) years. Aortic valve calcifications were present in
657 individuals (21.1 %) of whom 59 individuals (9.0 %)
developed a cardiovascular event. An example image of a
subject with a calcification in the aortic valve is displayed
in Fig. 1. Mitral valve calcifications were present in 85
individuals (2.7 %) of whom 11 developed a cardiovas-
cular event (12.9 %).
The plotted Schoenfeld residuals showed no relevant
deviations and thus the PH assumption was not violated
and therefore a multivariable Cox PH regression analysis
could be performed. For each variable the HR was calcu-
lated with 95 % CI. Bootstrap analysis resulted in an over-
optimism correction factor of 0.988. Corrected HRs with
95 % CI are listed in Table 2. Significant predictors in-
cluded current smoking status [HR for not smoking of 0.82
(0.72–0.93)], coronary calcium volume per 500 mm3 [HR
of 1.11 (95 % CI, 1.06–1.16)], aortic calcium volume per
500 mm3 [HR of 1.02 (95 % CI, 1.00–1.04)] and aortic
valve calcium volume per 500 mm3 [1.46 (95 % CI,
1.09–1.84)]. Mitral valve calcification volume was not a
significant predictor with an HR of 2.74 [95 % CI,
0.92–4.56] per 500 mm3.
An age-adjusted survival curve was evaluated by pres-
ence and absence of aortic valve calcifications (Fig. 2). The
curve indicates that the presence of heart valve calcifica-
tions translates in more events. The c-statistic of a basic
model with predictors proposed by Mets and colleagues
[15] including age, pack years, current smoking status,
coronary calcium volume and aorta calcium volume was
0.68 (95 % CI, 0.63–0.72). Adding both aortic valve and
mitral valve calcium volume to this basic model resulted in
a similar c-statistic of 0.68 (95 % CI, 0.64–0.73).
Discussion
We evaluated the prognostic value of aortic valve and
mitral valve/annulus calcifications for cardiovascular
events in male lung cancer screening participants without a
history of cardiovascular disease. The current study
showed that calcifications of the aortic valve increased
Fig. 1 Subject with a calcified aortic valve (a), and a subject with coronary and mitral annulus calcifications (b) Ao aorta, AoV aortic valve, PA
pulmonary artery, RA right atrium, LV left ventricle, MA mitral annulus, LAD left anterior descending coronary artery
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cardiovascular risk by almost 50 %. However, adding
cardiac valve calcium volumes did not substantially im-
prove a model proposed by Mets et al. [15] with age,
number of pack years, current smoking status, coronary
calcium volume and aorta calcium volume. Therefore,
assessment of cardiac valve calcifications on lung cancer
screening CT examinations is not recommended for
3 years cardiovascular risk assessment if calcifications of
the coronary arteries and aorta are also evaluated.
Lung cancer screening with non-gated unenhanced chest
CT is primarily aimed at lung cancer detection. However,
these CT examinations can also provide information about
other diseases including cardiovascular diseases, especially
since smoking is not only a risk factor for lung cancer, but
also for cardiovascular diseases [13, 15]. The current study
showed that cardiac valve calcifications were significantly
more prevalent in individuals who developed a cardiovas-
cular event compared to individuals without an event (31.7
vs 20.4 % for aortic valve calcifications and 5.9 vs 2.5 %
for mitral valve/annulus calcifications, respectively). These
numbers are comparable to previously reported prevalence
numbers of 18–27 % for aortic valve calcifications in
routine clinical care patients and an elderly population
based study [8, 24, 25] and 8–9 % for mitral valve calci-
fications in routine clinical care patients [24, 26]. If cardiac
valve calcifications were present, the volumes of these
calcifications were also significantly larger in individuals
who developed a cardiovascular event (179.1 vs 96.3 mm3
for aortic valve calcifications and 216.9 vs 140.8 mm3 for
mitral valve/annulus calcifications, respectively). This
indicates a potential prognostic value of cardiac valve
calcifications in a lung cancer screening setting, which was
confirmed by our multivariable cox PH regression analysis.
However, cardiac valve calcification volumes do not have
added predictive value after 3 years follow-up beyond age,
pack years, smoking status, coronary calcium volume and
aorta calcium volume. This may be explained by the
relatively short follow-up time of the current study. Prob-
ably calcifications of the coronaries and the aorta are as-
sociated with cardiovascular events on the short term,
whereas heart valve calcifications may be associated with
more chronic diseases. Another explanation may be the
etiology of cardiac valve calcifications that shares common
pathways and risk factors with coronary artery calcifica-
tion. Some studies indicate that calcifications of the coro-
nary arteries, the aorta and the cardiac valves are all part of
the progression of coronary atherosclerosis [27–29]. It is
suggested that especially micro calcifications in the coro-
naries and aorta are part of the atherosclerotic pathway
[30]. These may lead to plaque rupture and subsequently
myocardial infarction or stroke [30]. Besides part of the
atherosclerosis pathway, cardiac valve calcifications may
Table 2 Effects of predictors on 3 year risk on cardiovascular events (N = 3111)
Predictor Beta SE P value Hazard ratio (95 % CI)
Age (per 10 years) 0.223 0.149 0.1295 1.25 (0.96–1.54)
Former smoker -0.193 0.054 0.0003 0.82 (0.72–0.93)
Pack years (per 10 years) 0.118 0.075 0.1125 1.13 (0.98–1.27)
Coronary calcium volume (per 500 mm3) 0.102 0.027 0.0001 1.11 (1.06–1.16)
Aortic calcium volume (per 500 mm3) 0.021 0.010 0.0423 1.02 (1.00–1.04)
Aortic valve calcium volume (per 500 mm3) 0.381 0.191 0.0430 1.46 (1.09–1.84)
Mitral valve/annulus calcium volume (per 500 mm3) 1.007 0.928 0.2718 2.74 (0.92–4.56)
Corrected for over-optimism with a correction factor of 0.988
Significant values are marked bold
Fig. 2 Survival curve for aortic valve calcifications adjusted for an
age category of 55–60 years
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also be a cause of valve failure [31]. Large calcifications of
the aortic valve for example, may lead to impaired leaflet
function followed by heart failure [30]. Calcifications of
the mitral annulus are part of a chronic non-inflammatory
degenerative process [32], and severe calcifications of the
mitral annulus may cause mitral regurgitation [31].
Therefore, cardiac valve calcifications should be reported
in the clinical radiology routine where individual risk
factors may be unknown [33, 34].
The current study confirms and expands the results of
Gondrie et al. [24]. They also evaluated the prognostic
value of cardiac valve calcifications on future cardiovas-
cular events. However, they evaluated a more heteroge-
neous routine care population with routine radiation dose
chest CT exams (both with and without contrast medium)
and they used a subjective assessment instead of the
quantitative volume measurements as used in the current
study. Gondrie et al. also found increased HRs for cardiac
valve calcifications, but similar to our results cardiac valve
calcifications lost their prognostic value for cardiovascular
events when modelled with calcifications of the coronaries
and aorta. They also had a relatively short follow-up.
An in-house developed software package was used for
quantification of calcifications. Cardiac regions with
Hounsfield units of 130 and higher were detected as cal-
cium with this software package. This is similar to the
validated Agatston score. However, the Agatston score was
developed and validated for quantifying coronary calcifi-
cations on dedicated cardiac CT and not for cardiac valve
calcifications on non-gated low-dose chest CT. Therefore,
calcium quantification may be affected due to motion ar-
tifacts and worse image quality. However, newer CT sys-
tems result potentially in less artifacts and better image
quality as compared to the 16-slice CT systems that are
used in the current study.
Our study has limitations that should be addressed. First,
despite the large sample size of the current study, only men
and only (previous) smokers were included. Results may
thus not be generalizable to women and non-smoking in-
dividuals. The latter is less relevant since this study is fo-
cused on additional information provided by lung cancer
screening CT exams. Second, since not all Framingham
risk score determinants were provided by the NELSON
trial, the added value of cardiac valve calcifications beyond
the Framingham risk score could not be assessed. However,
we did include coronary artery calcium in our analyses, a
direct measure of vascular disease, which has been proven
to be a strong predictor for future cardiovascular events
[35, 36], and is considered a reflection of the impact of
known and unknown risk factors on the arterial wall. Third,
our follow-up time was relatively short and therefore the
emphasis was more on acute than on chronic disease. It
may be that heart valve calcifications lead to cardiovascular
events in the long term. Fourth, the NELSON lung cancer
screening trial was designed and powered for lung cancer
screening detection and not for cardiovascular events.
Fifth, not only hard events but also soft events were in-
cluded as outcome measures. Finally, the confidence in-
terval for the HR of mitral valve/annulus calcification
volumes was wider compared to aortic valve calcification
volumes. This is presumably caused by the low prevalence
of mitral valve/annulus calcifications (2.7 %) compared to
the higher prevalence of aortic valve calcifications
(21.1 %). Therefore, only a trend towards increased risk on
future cardiovascular events could be evaluated for mitral
valve/annulus calcifications. Moreover, van Hamersvelt
et al. [18] showed that the reproducibility of mitral valve/
annulus calcifications on lung cancer screening chest CT
exams is not as good as for aortic valve calcifications. This
may have contributed to weaker results for mitral valve/
annulus calcifications as compared to aortic valve
calcifications.
In conclusion, calcifications of the aortic valve are
predictors for future cardiovascular events. However, there
was no added prognostic value of cardiac valve calcium
volumes beyond age, number of pack years, current
smoking status, coronary calcium volume and aorta calci-
um volume for 3 years cardiovascular outcome.
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